Literature DB >> 19066569

A chromatin assay for human brain tissue.

Anouch Matevossian1, Schahram Akbarian.   

Abstract

Chronic neuropsychiatric illnesses such as schizophrenia, bipolar disease and autism are thought to result from a combination of genetic and environmental factors that might result in epigenetic alterations of gene expression and other molecular pathology. Traditionally, however, expression studies in postmortem brain were confined to quantification of mRNA or protein. The limitations encountered in postmortem brain research such as variabilities in autolysis time and tissue integrities are also likely to impact any studies of higher order chromatin structures. However, the nucleosomal organization of genomic DNA including DNA:core histone binding - appears to be largely preserved in representative samples provided by various brain banks. Therefore, it is possible to study the methylation pattern and other covalent modifications of the core histones at defined genomic loci in postmortem brain. Here, we present a simplified native chromatin immunoprecipitation (NChIP) protocol for frozen (never-fixed) human brain specimens. Starting with micrococcal nuclease digestion of brain homogenates, NChIP followed by qPCR can be completed within three days. The methodology presented here should be useful to elucidate epigenetic mechanisms of gene expression in normal and diseased human brain.

Entities:  

Mesh:

Year:  2008        PMID: 19066569      PMCID: PMC2586869          DOI: 10.3791/717

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  6 in total

1.  Immunoprecipitation of native chromatin: NChIP.

Authors:  Laura P O'Neill; Bryan M Turner
Journal:  Methods       Date:  2003-09       Impact factor: 3.608

2.  Chromatin immunoprecipitation in postmortem brain.

Authors:  Hsien-Sung Huang; Anouch Matevossian; Yan Jiang; Schahram Akbarian
Journal:  J Neurosci Methods       Date:  2006-03-30       Impact factor: 2.390

3.  Histone methylation at gene promoters is associated with developmental regulation and region-specific expression of ionotropic and metabotropic glutamate receptors in human brain.

Authors:  Florian Stadler; Gabriele Kolb; Lothar Rubusch; Stephen P Baker; Edward G Jones; Schahram Akbarian
Journal:  J Neurochem       Date:  2005-07       Impact factor: 5.372

4.  Identification of the transcriptional targets of FOXP2, a gene linked to speech and language, in developing human brain.

Authors:  Elizabeth Spiteri; Genevieve Konopka; Giovanni Coppola; Jamee Bomar; Michael Oldham; Jing Ou; Sonja C Vernes; Simon E Fisher; Bing Ren; Daniel H Geschwind
Journal:  Am J Hum Genet       Date:  2007-10-31       Impact factor: 11.025

5.  Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters.

Authors:  Hsien-Sung Huang; Anouch Matevossian; Catheryne Whittle; Se Young Kim; Armin Schumacher; Stephen P Baker; Schahram Akbarian
Journal:  J Neurosci       Date:  2007-10-17       Impact factor: 6.167

6.  GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia.

Authors:  Hsien-Sung Huang; Schahram Akbarian
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

  6 in total
  9 in total

1.  Generation of Calhm1 knockout mouse and characterization of calhm1 gene expression.

Authors:  Junbing Wu; Shengyi Peng; Rong Wu; Yumin Hao; Guangju Ji; Zengqiang Yuan
Journal:  Protein Cell       Date:  2012-06-21       Impact factor: 14.870

2.  Neuronal Kmt2a/Mll1 histone methyltransferase is essential for prefrontal synaptic plasticity and working memory.

Authors:  Mira Jakovcevski; Hongyu Ruan; Erica Y Shen; Aslihan Dincer; Behnam Javidfar; Qi Ma; Cyril J Peter; Iris Cheung; Amanda C Mitchell; Yan Jiang; Cong L Lin; Venu Pothula; A Francis Stewart; Patricia Ernst; Wei-Dong Yao; Schahram Akbarian
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

Review 3.  Transcriptional regulation of GAD1 GABA synthesis gene in the prefrontal cortex of subjects with schizophrenia.

Authors:  Amanda C Mitchell; Yan Jiang; Cyril Peter; Schahram Akbarian
Journal:  Schizophr Res       Date:  2014-10-31       Impact factor: 4.939

4.  Investigation of genes important in neurodevelopment disorders in adult human brain.

Authors:  Gilles Maussion; Alpha B Diallo; Carolina O Gigek; Elizabeth S Chen; Liam Crapper; Jean-Francois Théroux; Gary G Chen; Cristina Vasuta; Carl Ernst
Journal:  Hum Genet       Date:  2015-07-21       Impact factor: 4.132

Review 5.  The future of neuroepigenetics in the human brain.

Authors:  Amanda Mitchell; Panos Roussos; Cyril Peter; Nadejda Tsankova; Schahram Akbarian
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

6.  Analysis of somatic mutations in 131 human brains reveals aging-associated hypermutability.

Authors:  Taejeong Bae; Liana Fasching; Yifan Wang; Joo Heon Shin; Milovan Suvakov; Yeongjun Jang; Scott Norton; Caroline Dias; Jessica Mariani; Alexandre Jourdon; Feinan Wu; Arijit Panda; Reenal Pattni; Yasmine Chahine; Rebecca Yeh; Rosalinda C Roberts; Anita Huttner; Joel E Kleinman; Thomas M Hyde; Richard E Straub; Christopher A Walsh; Alexander E Urban; James F Leckman; Daniel R Weinberger; Flora M Vaccarino; Alexej Abyzov
Journal:  Science       Date:  2022-07-28       Impact factor: 63.714

Review 7.  Epigenetic regulation in human brain-focus on histone lysine methylation.

Authors:  Schahram Akbarian; Hsien-Sung Huang
Journal:  Biol Psychiatry       Date:  2008-09-24       Impact factor: 13.382

Review 8.  The molecular pathology of schizophrenia--focus on histone and DNA modifications.

Authors:  Schahram Akbarian
Journal:  Brain Res Bull       Date:  2009-09-01       Impact factor: 4.077

9.  H3K4 tri-methylation in synapsin genes leads to different expression patterns in bipolar disorder and major depression.

Authors:  Cristiana Cruceanu; Martin Alda; Corina Nagy; Erika Freemantle; Guy A Rouleau; Gustavo Turecki
Journal:  Int J Neuropsychopharmacol       Date:  2012-05-09       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.